CYDY Stock Price: CytoDyn Inc set to skyrocket as Phase 2 coronavirus cure trial looks promising
|- OTCMKTS: CYDY stock may surge after reporting significant results from a COVID-19 cure trial.
- CytoDyn is at an advanced stage, completing Phase 2 and may enter Phase 3 with its leronlimab medication.
- Competition is fierce and attention is growing after Russia registered its first coronavirus vaccine.
CytoDyn, a biotechnology company that spans the border between Canada and the US around Vancouver and Washington, announced a promising development. Its Phase 2 trial for COVID-19 has shown significant top-line results, opening the door to conducting a broad Phase 3 trial.
The leronlimab drug helps mild to moderate COVID-19 patients, that show an improvement in clinical symptoms versus the
From the firm's announcement:
Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab
Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 scale (NEWS2)
Earlier in the day, Russia's President Vladimir Putin announced that his country reported the first coronavirus vaccine. However, many doubt that Moscow's announcement is based on a rigorous experiment.
cytodyn inc Stock
OTCMKTS: CYDY
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.